Brazilian plant shows promise against arthritis in lab tests

A traditional Brazilian plant known as Joseph's Coat has demonstrated significant anti-inflammatory effects in laboratory studies, potentially offering a new natural treatment for arthritis. Researchers from three Brazilian universities confirmed the plant's ability to reduce swelling and protect joint tissue while showing a safe profile at tested doses. However, further clinical trials are needed before human use.

Scientists in Brazil have validated the long-standing folk use of Joseph's Coat (Alternanthera littoralis), a coastal plant, for treating inflammation and related conditions. The study, involving researchers from the Federal University of Grande Dourados (UFGD), the State University of Campinas (UNICAMP), and São Paulo State University (UNESP), was published in the Journal of Ethnopharmacology.

The investigation began with a chemical analysis of the ethanolic extract from the plant's aerial parts, led by pharmacist Marcos Salvador at UNICAMP's Institute of Biology. This identified bioactive compounds responsible for potential medicinal properties. Pharmacologist Cândida Kassuya from UFGD's Faculty of Health Sciences then tested the extract in experimental arthritis models, observing reduced edema and improved joint function. Toxicological assessments, coordinated by Arielle Cristina Arena from UNESP's Institute of Biosciences in Botucatu, confirmed safety at therapeutic doses.

"In the experimental models, we observed reduced edema, improved joint parameters, and modulation of inflammatory mediators, suggesting antioxidant and tissue-protective actions," Arena explained. The results indicate the extract not only alleviates swelling but also safeguards joint tissue from damage in inflammatory diseases like arthritis.

While promising, the team stresses that the plant is not yet suitable for clinical application. Additional human trials, standardized preparation, and regulatory approvals are essential. This work, funded by FAPESP through projects including 06/06079-4 and 21/09693-5, aims to scientifically support Brazil's biodiversity and traditional knowledge for safe natural product use.

The full study, titled "Ethanolic extract of Alternanthera littoralis P. Beauv. aerial parts: Safety assessment and efficacy in experimental models of articular," appears in the 2026 issue (volume 355, article 120720).

Related Articles

Illustration of Anvisa approving medical cannabis cultivation in Brazil, featuring scientists in a lab with plants and official documents.
Image generated by AI

Anvisa approves cannabis cultivation for medical purposes

Reported by AI Image generated by AI

The National Health Surveillance Agency (Anvisa) approved, on January 28, 2026, resolutions allowing cannabis cultivation for health treatments and research, along with new administration routes and plant imports. This step marks progress in the national production chain, easing access to plant-derived medicines. The changes broaden options for patients with severe illnesses while upholding strict restrictions.

Cuban President Miguel Díaz-Canel presented preliminary positive results from clinical trials of the biotechnological drug Jusvinza in patients with chronic post-chikungunya arthritis. The studies, started in December 2025, show notable improvements in provinces like Havana and Matanzas. Experts highlight the drug's safety profile and potential to slow inflammation.

Reported by AI

Researchers from Famerp, supported by Fapesp, tested anakinra to reduce inflammation in kidneys from deceased donors, enhancing their transplant viability. The study, awarded at the 2025 Latin American Transplant Congress, yielded promising results in pig kidneys. In Brazil, 60% to 70% of patients face post-transplant complications.

Brazil's National Health Surveillance Agency (Anvisa) approved the drug lecanemabe, marketed as Leqembi, on Thursday, January 8, for patients with early-stage Alzheimer's. The monoclonal antibody, administered via infusion, slows disease progression in individuals with mild cognitive impairment and confirmed beta-amyloid protein in the brain. The approval marks progress, though it is not a cure.

Reported by AI

Archaeologists have uncovered traces of plant toxins on arrowheads dating back 60,000 years in South Africa, providing the oldest direct evidence of ancient hunters using poisons. This discovery pushes back the known timeline for such practices by tens of thousands of years. The findings highlight early human sophistication in exploiting plant biochemistry.

Chef and researcher Bel Coelho launches her book 'Floresta na Boca' on Monday (12) at 7 p.m. at Livraria da Travessa in Lisbon. The work stems from a 2025 expedition through Pará, exploring Amazonian food and its producers. The event features a chat with writer Jerônimo Villas-Bôas, moderated by Alexandra Prado Coelho.

Reported by AI

Takeda Pharmaceutical has announced that its AI-assisted oral psoriasis drug zasocitinib proved safe and effective in late-stage trials. The once-daily pill outperformed placebo and the existing therapy apremilast in clearing skin for patients with moderate-to-severe plaque psoriasis. If approved, it would mark one of the first drugs discovered with artificial intelligence.

 

 

 

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline